Long-term study of ORX750 for narcolepsy and idiopathic hypersomnia
Part of Brain & nervous system, Mental health clinical trials.
This trial is for people who have already completed the main CRYSTAL-1 study of ORX750. It tests the long-term safety and effects of the drug, so you can continue treatment if it was helping you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with narcolepsy type 1, narcolepsy type 2, or idiopathic hypersomnia.
- You must have finished the full treatment period in the earlier CRYSTAL-1 study of ORX750.
- You must be willing and able to follow the study rules and procedures.
- You cannot have developed a new medical condition that would make it unsafe to stay in the study.
- You cannot take other medications for narcolepsy or idiopathic hypersomnia while in this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ORX750 for people with narcolepsy or idiopathic hypersomnia. You would need to stop your current sleepiness medicines to see if ORX750 helps reduce daytime sleepiness.
This study continues treatment with the investigational drug ALKS 2680 for people who have already completed a previous ALKS 2680 study for narcolepsy or idiopathic hypersomnia. It aims to see how safe and effective the drug is over a longer period.
This study tests an investigational drug called ALKS 2680 for people with narcolepsy type 2, a condition that causes excessive daytime sleepiness without sudden muscle weakness. The goal is to see if the drug is safe and helps reduce daytime sleepiness.
This study tests a new medication, ALKS 2680, to see if it helps reduce daytime sleepiness and other symptoms in adults with narcolepsy type 1. It may offer a new treatment option for people with this condition.
This Phase 2/3 study tests TAK-861 in people with narcolepsy type 1 (NT1) who already completed an earlier TAK-861 trial. The goal is to see if the medicine remains safe and effective for ongoing central (brain-related) sleepiness problems.
This study tests whether a new medication called cleminorexton helps people with narcolepsy (a condition causing severe daytime sleepiness) sleep better and feel more alert. You would take this medication instead of your current narcolepsy drugs for several months to see if it works.
Hear when a new Narcolepsy Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.